Our research broadens the knowledge of kidney disease.

Read up-to-date Nephrology faculty research on Pubmed with the link below

University of Washington Nephrology Faculty Research on Pubmed

We are committed to conducting path-breaking research in order to improve the lives of people with kidney diseases. Our faculty consistently publish new research in nationally recognized journals.

A selection of recent papers:


Prognostic Value of Echocardiography for Heart Failure and Death in Adults with Chronic Kidney Disease

Fitzpatrick JK, Ambrosy AP, Parikh RV, Tan TC, Bansal N, Go AS; CRIC Study Investigators.

Background: Adults with chronic kidney disease (CKD) are at increased risk of heart failure (HF) morbidity and mortality. Despite well-characterized abnormalities in cardiac structure in CKD, it remains unclear how to optimally leverage echocardiography to risk stratify CKD patients. Methods: We evaluated associations between echocardiographic parameters and risk of HF hospitalization and death using Cox proportional hazard models and forward selection with integrated discrimination improvement (IDI).

Long-term Outcomes Among Patients With Advanced Kidney Disease Who Forgo Maintenance Dialysis

Susan P Y Wong, Tamara Rubenzik, Leila Zelnick, Sara N Davison, Diana Louden, Taryn Oestreich, Ann L Jennerich

Question: What are the long-term outcomes of patients with advanced kidney disease who do not pursue maintenance dialysis? Findings: In this systematic review of 41 cohort studies comprising 5102 adults with advanced kidney disease who did not pursue dialysis, limited available evidence suggests that many patients survived several years and experienced the sustained quality of life until late in their illness course. However, the use of acute care services was common, and there was a substantial disparity in access to supportive care near the end of life across cohorts. Meaning: These findings suggest that advances in research and health care delivery are needed to optimize outcomes among patients who are not treated with dialysis.

Optimizing Risk Assessment In Simultaneous Liver and Kidney Transplant: Donor and Recipient Factors Associated With Improved Outcome

Hendele, J.B., Perkins, J.D., Leca, N., Biggins, S.W., Sibulesky, L.

Standardization in allocation of kidneys for transplant simultaneous with livers and the creation of a “safety net” for kidney transplant after liver transplant alone (LTA) was designed to encourage clinicians to list patients for LTA when the likelihood of renal recovery and the necessity of simultaneous liver and kidney (SLK) transplant were unclear. We analyzed the United Network for Organ Sharing database of SLK recipients starting January 1, 2015. Organs from one deceased donor were used in each individual case.

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

Li PK, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T, Kanjanabuch T, Kim YL, Madero M, Malyszko J, Mehrotra R, Okpechi IG, Perl J, Piraino B, Runnegar N, Teitelbaum I, Wong JK, Yu X, Johnson DW

Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD and prevention and treatment of such is important in reducing patient morbidity and mortality. The ISPD 2022 updated recommendations have revised and clarified definitions for refractory peritonitis, relapsing peritonitis, peritonitis-associated catheter removal, PD-associated hemodialysis transfer, peritonitis-associated death, and peritonitis-associated hospitalization. New peritonitis categories and outcomes including pre-PD peritonitis, enteric peritonitis, catheter-related peritonitis, and medical cure are defined.

Changing the Trajectory of Heart Failure and Kidney Disease

Rangaswami J, Bhalla V, Chertow G, Harrington R, Staruschenko A, Tuttle K, Braunwald E.

This is a PDF-only article.

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

EMPA-KIDNEY Collaborative Group, includes KR Tuttle, et al

Background: The effects of the sodium-glucose co-transporter-2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). Methods: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily reduces risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had:

Clinic, Home, and Kiosk Blood Pressure Measurements for Diagnosing Hypertension: a Randomized Diagnostic Study

Green BB, Anderson ML, Cook AJ, Ehrlich K, Hall YN, Hsu C, Joseph D, Klasnja P, Margolis KL, McClure JB, Munson SA, Thompson MJ.

Home participants received a validated Bluetooth-enabled oscillometric Omron N786 BP monitor17 with an appropriately sized upper-arm cuff to take duplicate measurements twice daily for 5 days: after rising and at bedtime (total 20 measurements).18 Home BPs were collected by study staff via Bluetooth. Kiosk participants were asked to measure BP using validated PharmaSmart BP kiosks19 at KPWA clinics or nearby pharmacies, with triplicate measurements on three separate days.20 Measurements were linked to participants via a kiosk smartcard and collected using the vendor’s cloud-based service.

Microphysiological systems in absorption, distribution, metabolism, and elimination sciences

Kirk P. Van Ness, Francine Cesar, Catherine K. Yeung, Jonathan Himmelfarb, Edward J. Kelly

The use of microphysiological systems (MPS) to support absorption, distribution, metabolism, and elimination (ADME) sciences has grown substantially in the last decade, in part driven by regulatory demands to move away from traditional animal‐based safety assessment studies and industry desires to develop methodologies to efficiently screen and characterize drugs in the development pipeline. The past decade of MPS development has yielded great user‐driven technological advances with the collective fine‐tuning of cell culture techniques, fluid delivery systems, materials engineering, and performance enhancing modifications.

Biochemical Markers of Bone Turnover in Older Adults with Type 1 Diabetes.

Rubin MR, de Boer IH, Backlund JC, Arends V, Gubitosi-Klug R, Wallia A, Sinha Gregory N, Barnie A, Burghardt AJ, Lachin JM, Braffett BH, Schwartz AV.

Context: Type 1 diabetes (T1D) is characterized by high fracture risk, yet little is known regarding diabetes-related mechanisms or risk factors.Objective: Determine if glycemic control, advanced glycation end products (AGEs), and microvascular complications are associated with bone turnover markers among older T1D adults.

Serum Protein Exposure Activates a Core Regulatory Program Driving Human Proximal Tubule Injury

Lidberg K, Muthusamy S, Adil M, Mahadeo A, Yang J, Patel R, Wang L, Bammler T, Reichel J, Yeung C, Himmelfarb J, Kelly E, Akilesh S.

The kidneys efficiently filter waste products while retaining serum proteins in the circulation. However, numerous diseases compromise this barrier function, resulting in spillage of serum proteins into the urine (proteinuria). Some studies of glomerular filtration suggest that tubules may be physiologically exposed to nephrotic-range protein levels. Therefore, whether serum components can directly injure the downstream tubular portions of the kidney, which in turn can lead to inflammation and fibrosis, remains controversial.